Through the partnership, whose value was not disclosed, AbCellera’s platform will identify therapeutic antibodies against up to six targets—to be selected by Moderna—by searching and analyzing natural immune responses. Moderna and AbCellera are not disclosing which therapeutic areas the antibodies will address. “What I can say is that it's not a collaboration that's restricted to infectious disease,” AbCellera CEO and co-founder Carl Hansen, PhD, told GEN Edge . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge